4.6 Article

Virtual Screening for FDA-Approved Drugs That Selectively Inhibit Arginase Type 1 and 2

Journal

MOLECULES
Volume 27, Issue 16, Pages -

Publisher

MDPI
DOI: 10.3390/molecules27165134

Keywords

virtual screening; molecular docking; ARG1; ARG2; arginase; vina; FDA

Funding

  1. Katz Foundation
  2. Ginsburg Foundation

Ask authors/readers for more resources

Arginases are overexpressed in human diseases, making them important targets for developing anti-aging and antineoplastic drugs. In this study, a virtual screening of 2115 FDA-approved drug molecules was conducted to identify potential arginase ligands. The results showed that half of the top 30 potential drugs are already used clinically for various conditions, validating the virtual screening approach. The three identified categories of potential arginase ligands greatly expand the selectivity of arginase inhibition.
Arginases are often overexpressed in human diseases, and they are an important target for developing anti-aging and antineoplastic drugs. Arginase type 1 (ARG1) is a cytosolic enzyme, and arginase type 2 (ARG2) is a mitochondrial one. In this study, a dataset containing 2115-FDA-approved drug molecules is virtually screened for potential arginase binding using molecular docking against several ARG1 and ARG2 structures. The potential arginase ligands are classified into three categories: (1) Non-selective, (2) ARG1 selective, and (3) ARG2 selective. The evaluated potential arginase ligands are then compared with their clinical use. Remarkably, half of the top 30 potential drugs are used clinically to lower blood pressure and treat cancer, infection, kidney disease, and Parkinson's disease thus partially validating our virtual screen. Most notable are the antihypertensive drugs candesartan, irbesartan, indapamide, and amiloride, the antiemetic rolapitant, the anti-angina ivabradine, and the antidiabetic metformin which have minimal side effects. The partial validation also favors the idea that the other half of the top 30 potential drugs could be used in therapeutic settings. The three categories greatly expand the selectivity of arginase inhibition.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available